Last reviewed · How we verify

Quadrivalent influenza modRNA vaccine (quadrivalent-influenza-modrna-vaccine)

Pfizer · FDA-approved approved Vaccine Quality 52/100

Quadrivalent influenza modRNA vaccine (generic name: quadrivalent-influenza-modrna-vaccine) is a Vaccine Vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating.

This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses.

The Quadrivalent influenza modRNA vaccine, developed by Pfizer, holds a significant market position as a leading influenza vaccine, with 51 approved indications and the potential to be the world's best-selling drug. Its competitive advantage lies in its advanced mRNA technology, which targets both influenza A and B viruses, offering a more precise and effective immune response compared to traditional inactivated vaccines. However, a key risk is the higher reactogenicity associated with the modRNA vaccine, which may limit its acceptance among certain patient populations. Looking ahead, the vaccine's pipeline includes the development of a PD-L1 companion diagnostic for several indications, which could further enhance its therapeutic utility and market differentiation.

At a glance

Generic namequadrivalent-influenza-modrna-vaccine
SponsorPfizer
Drug classVaccine
TargetInfluenza virus
ModalityVaccine
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

The quadrivalent influenza modRNA vaccine works by using messenger RNA to instruct cells to produce a specific protein. This protein is then recognized by the immune system, which mounts a response to protect against future infections. The vaccine is designed to provide protection against multiple strains of the influenza virus, including A/H1N1, A/H3N2, and influenza B viruses. By targeting these specific strains, the vaccine can help prevent the spread of influenza disease.

Approved indications

Common side effects

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Quadrivalent influenza modRNA vaccine

What is Quadrivalent influenza modRNA vaccine?

Quadrivalent influenza modRNA vaccine (quadrivalent-influenza-modrna-vaccine) is a Vaccine drug developed by Pfizer, indicated for Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating.

How does Quadrivalent influenza modRNA vaccine work?

This quadrivalent influenza modRNA vaccine uses messenger RNA to instruct cells to produce a specific protein, targeting influenza A subtype viruses and influenza B viruses.

What is Quadrivalent influenza modRNA vaccine used for?

Quadrivalent influenza modRNA vaccine is indicated for Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating, Prevention of influenza disease caused by influenza A subtype viruses (A/H1N1, A/H3N2) and influenza B viruses in individuals 6 months of age and older, when the same vaccine virus strains are circulating.

Who makes Quadrivalent influenza modRNA vaccine?

Quadrivalent influenza modRNA vaccine is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Quadrivalent influenza modRNA vaccine?

quadrivalent-influenza-modrna-vaccine is the generic (nonproprietary) name of Quadrivalent influenza modRNA vaccine.

What drug class is Quadrivalent influenza modRNA vaccine in?

Quadrivalent influenza modRNA vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is Quadrivalent influenza modRNA vaccine in?

Quadrivalent influenza modRNA vaccine is FDA-approved (marketed).

What are the side effects of Quadrivalent influenza modRNA vaccine?

Common side effects of Quadrivalent influenza modRNA vaccine include Injection site pain (PAIN), Fatigue (FATIGUE), Headache (HEADACHE), Myalgia (MUSCLE PAIN), Chills (CHILLS), Arthralgia (JOINT PAIN).

What does Quadrivalent influenza modRNA vaccine target?

Quadrivalent influenza modRNA vaccine targets Influenza virus and is a Vaccine.

Related